Literature DB >> 2848100

Strategic approaches to drug design. II. Modelling studies on phosphodiesterase substrates and inhibitors.

A Davis1, B H Warrington, J G Vinter.   

Abstract

Modelling studies have been carried out on the phosphodiesterase (PDE) substrates, adenosine- and guanosine-3'5'-cyclic monophosphates, and on a number of non-specific and type III-specific phosphodiesterase inhibitors. These studies have assisted the understanding of PDE substrate differentiation and the design of potent, selective PDE type III inhibitors.

Mesh：

Substances：

Year:  1987        PMID： 2848100     DOI： 10.1007/bf01676955

Source DB:  PubMed          Journal:  J Comput Aided Mol Des        ISSN： 0920-654X            Impact factor:   3.686


  16 in total

1.  Selective inhibition of cyclic nucleotide phosphodiesterases by analogues of 1-methyl-3-isobutylxanthine.

Authors:  G L Kramer; J E Garst; S S Mitchel; J N Wells
Journal:  Biochemistry       Date:  1977-07-26       Impact factor: 3.162

2.  Determination of the syn-anti equilibrium of some purine 3':5'-nucleotides by nuclear-magnetic-relaxation perturbation in the presence of a lanthanide-ion probe.

Authors:  G V Fazakerley; J C Russell; M A Wolfe
Journal:  Eur J Biochem       Date:  1977-06-15

3.  Complementary base pairing and the origin of substitution mutations.

Authors:  M D Topal; J R Fresco
Journal:  Nature       Date:  1976-09-23       Impact factor: 49.962

Review 4.  A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity.

Authors:  R E Weishaar; M H Cain; J A Bristol
Journal:  J Med Chem       Date:  1985-05       Impact factor: 7.446

5.  Conformations of cyclic 3',5'-nucleotides. Effect of the base on the synanti conformer distribution.

Authors:  N Yathindra; M Sundaralingam
Journal:  Biochem Biophys Res Commun       Date:  1974-01       Impact factor: 3.575

6.  Activating effects of AR-L 115 BS on the Ca2+ sensitive force, stiffness and unloaded shortening velocity (Vmax) in isolated contractile structures from mammalian heart muscle.

Authors:  J W Herzig; K Feile; J C Rüegg
Journal:  Arzneimittelforschung       Date:  1981

Review 7.  Identification and properties of cyclic nucleotide phosphodiesterases.

Authors:  J A Beavo; R S Hansen; S A Harrison; R L Hurwitz; T J Martins; M C Mumby
Journal:  Mol Cell Endocrinol       Date:  1982 Nov-Dec       Impact factor: 4.102

8.  The identification of a new cyclic nucleotide phosphodiesterase activity in human and guinea-pig cardiac ventricle. Implications for the mechanism of action of selective phosphodiesterase inhibitors.

Authors:  M L Reeves; B K Leigh; P J England
Journal:  Biochem J       Date:  1987-01-15       Impact factor: 3.857

9.  Cardiotonic agents. 4. Synthesis and biological evaluation of N-substituted 2,4,4a,5-tetrahydro-3H-indeno[1,2-c]pyridazin-3-ones: rigid structures derived from CI-930 and analogues.

Authors:  I Sircar; B L Duell; M H Cain; S E Burke; J A Bristol
Journal:  J Med Chem       Date:  1986-11       Impact factor: 7.446

10.  Bipyridine cardiotonics: the three-dimensional structures of amrinone and milrinone.

Authors:  D W Robertson; E E Beedle; J K Swartzendruber; N D Jones; T K Elzey; R F Kauffman; H Wilson; J S Hayes
Journal:  J Med Chem       Date:  1986-05       Impact factor: 7.446
View more
  6 in total

1.  On the electrostatic and steric similarity of lactam compounds and the natural substrate for bacterial cell-wall biosynthesis.

Authors:  J Frau; S L Price
Journal:  J Comput Aided Mol Des       Date:  1996-04       Impact factor: 3.686

2.  Multiconformational composite molecular potential fields in the analysis of drug action. I. Methodology and first evaluation using 5-HT and histamine action as examples.

Authors:  J G Vinter; K I Trollope
Journal:  J Comput Aided Mol Des       Date:  1995-08       Impact factor: 3.686

3.  Contemporary Computational Applications and Tools in Drug Discovery.

Authors:  Philip B Cox; Rishi Gupta
Journal:  ACS Med Chem Lett       Date:  2022-06-01       Impact factor: 4.632

4.  Relative binding orientations of adenosine A1 receptor ligands--a test case for Distributed Multipole Analysis in medicinal chemistry.

Authors:  E M van der Wenden; S L Price; R P Apaya; A P IJzerman; W Soudijn
Journal:  J Comput Aided Mol Des       Date:  1995-02       Impact factor: 3.686

5.  The matching of electrostatic extrema: a useful method in drug design? A study of phosphodiesterase III inhibitors.

Authors:  R P Apaya; B Lucchese; S L Price; J G Vinter
Journal:  J Comput Aided Mol Des       Date:  1995-02       Impact factor: 3.686

6.  The effect of SK&F 95654, a novel phosphodiesterase inhibitor, on cardiovascular, respiratory and platelet function.

Authors:  K J Murray; R J Eden; J S Dolan; D C Grimsditch; C A Stutchbury; B Patel; A Knowles; A Worby; J A Lynham; W J Coates
Journal:  Br J Pharmacol       Date:  1992-10       Impact factor: 8.739
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.